<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816916</url>
  </required_header>
  <id_info>
    <org_study_id>AXA1665-101</org_study_id>
    <nct_id>NCT04816916</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy</brief_title>
  <acronym>EMMPOWER</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EMMPOWER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axcella Health, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axcella Health, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a global study to compare the effects of AXA1665, an orally active mixture of amino&#xD;
      acids, compared to placebo, on cognitive and physical function, as well as the safety and&#xD;
      tolerability of AXA1665.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in neurocognitive function by Psychometric Hepatic Encephalopathy Score (PHES)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to and frequency of recurrent overt hepatic encephalopathy</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on physical function assessed by Liver Frailty Index (a composite measure of hand grip strength, balance and ability to stand up from a chair)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of study product emergent adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>AXA1665 53.8 g per day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AXA1665 administered orally TID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AXA1665</intervention_name>
    <description>AXA1665 administered TID with food</description>
    <arm_group_label>AXA1665 53.8 g per day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo administered TID with food</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to participate in the study and provide written informed consent.&#xD;
&#xD;
          -  Male and female adults aged &gt; 18 years.&#xD;
&#xD;
          -  History of cirrhosis and at least 1 documented prior episode of overt hepatic&#xD;
             encephalopathy within 24 weeks prior to Screening;&#xD;
&#xD;
          -  A PHES ≤ -4 during Screening&#xD;
&#xD;
          -  MELD-Na score of &lt;20 at Screening&#xD;
&#xD;
          -  Support of a primary caregiver who is able and willing to give written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospitalization or serious medical condition&#xD;
&#xD;
          -  History or presence of Child's Pugh class C, hepato-renal syndrome(s), refractory&#xD;
             ascites or spontaneous bacterial peritonitis (SBP)&#xD;
&#xD;
          -  History of a portosystemic or a transjugular intrahepatic portosystemic shunt (TIPS)&#xD;
             placement;&#xD;
&#xD;
          -  Expectation of a liver transplant during the study&#xD;
&#xD;
          -  Screening Alcohol Use Disorders Identification Test (AUDIT) score ≥8&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Duarte-Rojo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret Koziel, M.D.</last_name>
    <phone>1-857-320-2200</phone>
    <email>clinicaltrials@axcellaheath.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randi Wong</last_name>
    </contact>
    <contact_backup>
      <last_name>Jennifer Lai, M.D., M.B.A</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>OMEGA Research Consultants</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Cortese</last_name>
    </contact>
    <investigator>
      <last_name>Kwabena Ayesu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Hepatology Research at CTRB</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Briana Foerman</last_name>
    </contact>
    <contact_backup>
      <last_name>Giuseppe Morelli, M.D.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Homestead Associates in Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daydene Ordaz</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Fernandez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Terrell</last_name>
    </contact>
    <investigator>
      <last_name>Marwan Ghabril, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Polly Robarts</last_name>
    </contact>
    <investigator>
      <last_name>Paul Thuluvath, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mallory Ianelli, BSN, RN</last_name>
    </contact>
    <investigator>
      <last_name>Brett Fortune, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Person</last_name>
    </contact>
    <investigator>
      <last_name>John Poulos, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solution: Allied Digestive Disease Center</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Shabih</last_name>
    </contact>
    <investigator>
      <last_name>Babatunde Adeyefa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taryn Kruse</last_name>
    </contact>
    <contact_backup>
      <last_name>Robert Rahimi, M.D.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Optimed Research</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78359</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Schertzer</last_name>
    </contact>
    <investigator>
      <last_name>Rashmee Patil, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solution: Digestive Health Associates</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naghmeh Soltani, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Gowrappala Ramesh, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Liver Therapies at St. Luke's Episcopal Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Hashim</last_name>
    </contact>
    <contact_backup>
      <last_name>Prasun Jalal, M.D.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rena Summers</last_name>
    </contact>
    <investigator>
      <last_name>Stephen Harrison, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia School of Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Laskey</last_name>
    </contact>
    <investigator>
      <last_name>Matthew Stotts, M.D.. MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Soublet</last_name>
    </contact>
    <investigator>
      <last_name>Mitchell Shiffman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Taylor, MSN</last_name>
    </contact>
    <investigator>
      <last_name>Arun Sanyal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Cole</last_name>
    </contact>
    <investigator>
      <last_name>Stephen Congly, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMC Diabetes &amp; Endocrinology Ltd. - London</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 2C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patsy Burns, R.N.</last_name>
    </contact>
    <investigator>
      <last_name>Paul Marotta, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>end stage liver disease</keyword>
  <keyword>sarcopenia</keyword>
  <keyword>amino acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

